Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Bria-Pros+ is based on BriaCell's next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural killer cellsInitiation of GMP manufacturing represents a major milestone for BriaCell's off-the-shelf personalized cellular cancer vaccines PHILADELPHIA and VANCOUVER, British Columbia, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" o ...